Sexual Health

PT-141: Bremelanotide

A research overview of the melanocortin agonist PT-141 — its origin in Melanotan II research, its central MC4 receptor mechanism, the Phase 3 clinical evidence, and the safety and protocol data reported in the literature.

Export article
Glowing brain with the hypothalamus illuminated as a cyclic peptide binds a receptor

What It Is

PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide (7 amino acids). It is a melanocortin receptor agonist derived from Melanotan II, but engineered to be more selective. Where Melanotan II activates multiple melanocortin receptors and produces tanning, appetite suppression, and sexual effects together, PT-141 was developed to isolate the sexual-function component.

Mammals express five melanocortin receptors, MC1 through MC5. PT-141 primarily activates MC4, the receptor in the brain associated with regulating sexual arousal and desire. It also shows some activity at MC3 and MC1, but the sexual effects are driven by MC4 activation in the hypothalamus.

This is the key distinction between PT-141 and PDE5 inhibitors such as sildenafil or tadalafil. PDE5 inhibitors act on blood flow — they relax vascular smooth muscle to support the physical mechanics of an erection. PT-141 does not act on blood flow. It works through the central nervous system, activating receptors that govern desire and arousal. It addresses the want, not only the physical ability — which is why it has been studied in both men and women, including men who do not respond to PDE5 inhibitors.

PT-141 was developed by Palatin Technologies. Its discovery traces back to Melanotan II research at the University of Arizona in the 1990s, when an investigator accidentally self-administered roughly twice the intended dose of Melanotan II and experienced a prolonged erection. That observation led to the isolation of PT-141 as a more targeted compound.

In 2019, the FDA approved bremelanotide under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not approved for men, although trials in men with erectile dysfunction have reported positive results.

How It Works

MC4 Receptor Activation in the Hypothalamus

Following subcutaneous administration, PT-141 enters circulation and reaches the brain, where it binds MC4 receptors concentrated in the hypothalamus. Activation of these receptors increases dopamine release in the medial preoptic area — the neurotransmitter that drives desire, motivation, and reward. In effect, PT-141 turns up the gain on the brain's arousal circuitry.

A useful analogy: PDE5 inhibitors widen the pipes so more water can flow. PT-141 turns on the faucet. If the faucet is already running and the limitation is purely mechanical, a PDE5 inhibitor addresses it. If the faucet itself is barely running — low desire and arousal — PT-141 acts on the upstream signal that PDE5 inhibitors do not reach.

Central vs. Peripheral Mechanism

PT-141 does not lower blood pressure the way PDE5 inhibitors can, and it does not depend on nitric-oxide signaling in the vasculature. It acts at the level of the brain, influencing both psychological desire and the physiological arousal response. In men, this is why it has produced erections in subjects where PDE5 inhibitors failed — the failure point may lie upstream in the brain rather than downstream in the blood vessels.

Effects in Women

In women, PT-141 activates the same MC4 receptors, increasing dopamine-mediated arousal signaling. In trials this translated to increased desire, improved arousal, and greater satisfaction. The mechanism does not depend on hormonal status, so effects were observed independent of estrogen or testosterone levels.

Pharmacokinetics

  • Time to peak plasma concentration: ~1 hour (subcutaneous)
  • Half-life: ~2.7 hours
  • Subcutaneous bioavailability: ~100%
  • Metabolism: hydrolysis of peptide bonds
  • Excretion: ~65% urine, ~23% feces
  • Onset of effect: within ~45 minutes, with effects reported for 12–24 hours and occasionally up to 72 hours at higher doses

Areas of Research

  • Sexual desire and arousal: Increases in both subjective desire and the physical arousal response via central melanocortin signaling — relevant where the limiting factor is low desire rather than, or in addition to, vascular function.
  • Erectile function in men: Clinically meaningful erections in men with ED, including sildenafil non-responders — one trial reported a 33.5% response rate vs. 8.5% on placebo.
  • Female sexual dysfunction: The only FDA-approved injectable for HSDD in premenopausal women; the Phase 3 RECONNECT trials showed significant improvement in desire, reduced distress, and more satisfying sexual events.
  • Hormone independence: Because it acts through the melanocortin system rather than sex hormones, effects do not depend on testosterone or estrogen levels.

What the Science Shows

The clinical evidence for PT-141 is stronger than for most research peptides because it completed the full FDA approval process for at least one indication.

RECONNECT Phase 3 Trials (Women)

Two identical randomized, double-blind, placebo-controlled studies enrolled 1,247 premenopausal women with HSDD. Participants received 1.75 mg bremelanotide or placebo subcutaneously, as needed before anticipated sexual activity, for 24 weeks. Both trials showed statistically significant improvement in desire scores and a meaningful increase in satisfying sexual events vs. placebo (Clayton et al., Obstet Gynecol, 2019). A 52-week open-label extension showed sustained benefit without notable receptor desensitization (Kingsberg et al., 2019).

Trials in Men with ED

The male evidence base is smaller. In an early trial, men who did not achieve an adequate response on 100 mg sildenafil received 4 or 6 mg PT-141 subcutaneously; both doses produced a significant erectile response during visual sexual stimulation, measured by RigiScan penile-rigidity monitoring. In healthy men, responses became significant at doses above 1 mg. A larger randomized trial gave 342 sildenafil non-responders either a 10 mg intranasal PT-141 dose or placebo before intercourse: 33.5% responded on PT-141 vs. 8.5% on placebo, with more satisfying intercourse and more side effects in the active group.

A Phase 2 study is evaluating a co-formulation of PT-141 with a PDE5 inhibitor, targeting the central desire pathway and the peripheral vascular pathway simultaneously.

Blood Pressure

PT-141 produces a small, transient blood-pressure increase — a mean of roughly 2–3 mmHg systolic and diastolic, peaking 4–8 hours post-dose and returning to baseline by 12–24 hours. This is not clinically significant for most subjects but is relevant in uncontrolled hypertension.

Anecdotal Reports

The following summarizes commonly reported subjective experiences. It is anecdotal and does not carry the weight of controlled research.

  • Positive: A response often described as more natural than PDE5 inhibitors — an increase in genuine desire rather than only physical capability. Men describe improved erection quality, elevated libido for 12–24 hours, and greater sensitivity; women describe increased mental arousal, more frequent spontaneous desire, and greater satisfaction.
  • Negative: Nausea is the most common complaint, consistent with trial data. Others include facial flushing, warmth, mild fatigue, occasional headache, and — in some men at higher doses — uncomfortably persistent erections.
  • Dose-response: Higher doses are reported to produce stronger effects alongside more nausea, with most settling on the lowest dose that is effective.

Research Protocols Reported in the Literature

The parameters below document prior methodology from published trials and commonly reported practice — they are not dosing guidance.

Studied Doses

  • Approved label (HSDD, women): 1.75 mg subcutaneously at least 45 minutes before anticipated activity; no more than one dose per 24 hours and no more than 8 doses per month.
  • Men with ED: 4 or 6 mg subcutaneously in sildenafil partial-responders; 10 mg intranasally in sildenafil non-responders; significant responses in healthy men above 1 mg subcutaneously.
  • No published dose-finding studies exist for the off-label subcutaneous ranges commonly cited for libido research in men.

Commonly Reported Parameters

Standard Range

Amount:
1–2 mg subcutaneous
Timing:
As needed, 45–60 min prior
Maximum:
1 per 24 h, 8 per month
Site:
Abdomen or thigh

Nausea-Sensitive Titration

Start:
0.5 mg
Step up:
0.75 mg, then 1 mg
Goal:
Lowest effective, tolerable amount
Note:
Antiemetic pre-treatment is sometimes reported

Reconstitution Reference

Vial size10 mg
Bacteriostatic water2 mL
Concentration5 mg/mL — 500 mcg per 10 units (U-100 insulin syringe)
1 mg20 units
1.75 mg35 units
2 mg40 units

Combination Context

  • PT-141 + PDE5 inhibitors: The combination currently under clinical study. The two act through independent pathways — central desire vs. peripheral vascular. Both can influence blood pressure, so lightheadedness or dizziness is a monitoring point.
  • PT-141 + TRT: No known interaction; melanocortin and androgen receptor systems are independent. PT-141 targets a different mechanism where low libido persists despite normal androgen levels.
  • PT-141 + GH secretagogues (CJC-1295, Ipamorelin): No known interaction and no timing conflict — GH peptides are typically studied fasted; PT-141 is not.
  • PT-141 + Melanotan II: Not recommended together. Melanotan II already activates MC4 as part of its non-selective profile, so adding PT-141 is redundant and increases the risk of nausea and blood-pressure changes.
  • PT-141 + Kisspeptin: No known interaction. Kisspeptin acts on the HPG axis (GnRH and downstream testosterone); PT-141 acts on the melanocortin system — distinct aspects of sexual physiology.

Common Questions

How is PT-141 different from sildenafil?
Sildenafil inhibits PDE5 to relax vascular smooth muscle and increase blood flow. PT-141 activates brain MC4 receptors that increase dopamine and desire. One fixes the plumbing; the other turns on the faucet.
Has it been studied in women?
Yes — it is FDA approved for premenopausal women with HSDD, and the Phase 3 trials showed meaningful improvements in desire, arousal, and satisfaction via the same central pathway studied in men.
How quickly does it act?
Onset at roughly 45–60 minutes after subcutaneous administration, peak effects at 1–3 hours, with sustained effects reported for 12–72 hours.
Is it used daily?
No. It is used as needed; the approved label limits use to once per 24 hours and 8 times per month.
Does it cause spontaneous erections?
Not typically at standard doses, unlike Melanotan II. PT-141 increases desire and responsiveness to sexual cues rather than producing erections without stimulation.
What about PDE5 non-responders?
This is the population it was designed for. If PDE5 inhibitors are ineffective, the limitation may be upstream in the brain's arousal circuitry — the pathway PT-141 targets.

Side Effects

In Published Research

EffectReported Incidence
Nausea (median onset ~1 h, duration ~2 h)~40%
Flushing~20%
Injection-site reactions13%
Headache11%
Vomiting4.8%
Cough3.3%
Fatigue3.2%
Hot flashes2.7%
Paresthesia / tingling2.6%
Dizziness2.2%
Nasal congestion2.1%
Hyperpigmentation~1%

No significant hypertensive events and no cases of melanoma were reported in the clinical trials. Most effects were dose-dependent and temporary.

Contraindications and Precautions

  • Contraindicated: uncontrolled hypertension or significant cardiovascular disease; known hypersensitivity to bremelanotide.
  • Caution: controlled hypertension (monitor blood pressure); hepatic or renal impairment (not studied); pregnancy or breastfeeding (no safety data); any condition where transient blood-pressure increases could be dangerous.
  • Drug interactions: other agents that affect blood pressure; bremelanotide may reduce the effectiveness of oral naltrexone, and the FDA label recommends against concurrent use.

Regulatory Status

Bremelanotide is FDA approved (Vyleesi, 2019) for HSDD in premenopausal women only. It is not approved for men; Phase 2 trials have been completed and a combination trial is underway. BioPrime supplies PT-141 strictly as a reference compound for in-vitro and preclinical laboratory research.

References

  • Clayton AH, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899–908. PubMed
  • Kingsberg SA, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909–917. PMC
  • Clayton AH, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health. 2016;12(3):325–337. Journal
  • Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628–638. PubMed
  • Rosen RC, et al. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem. 2007;7(11):1137–1144. PubMed
  • Pfaus JG, et al. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007;4 Suppl 4:269–279. PubMed
  • Shin YC, et al. Novel emerging therapies for erectile dysfunction. World J Mens Health. 2021;39(1):44–64. PMC

Disclaimer

This information is not medical advice. Content is provided for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. BioPrime products are sold strictly for in-vitro laboratory research by qualified professionals. Results from any research protocol will vary based on usage, conditions, and methodology.